Public Profile

Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc, a leading biopharmaceutical company headquartered in Ireland (IE), focuses on developing innovative therapies for patients with central nervous system disorders. Founded in 1990, Avadel has established a strong presence in the global pharmaceutical industry, particularly in the United States and Europe. The company is renowned for its unique drug delivery technologies, which enhance the efficacy and safety of its core products, including treatments for narcolepsy and other sleep disorders. Avadel's commitment to addressing unmet medical needs has positioned it as a key player in the market, with notable achievements in regulatory approvals and partnerships that bolster its growth trajectory. With a focus on patient-centric solutions, Avadel Pharmaceuticals continues to advance its mission of improving lives through innovative healthcare solutions.

DitchCarbon Score

How does Avadel Pharmaceuticals plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

13

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

14

Industry Benchmark

Avadel Pharmaceuticals plc's score of 13 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.

58%

Avadel Pharmaceuticals plc's reported carbon emissions

Avadel Pharmaceuticals plc, headquartered in Ireland (IE), currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is unclear how the company is addressing its carbon footprint or contributing to climate action. In the absence of detailed information, it is essential to monitor their future disclosures for any developments regarding their climate commitments and sustainability efforts.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Avadel Pharmaceuticals plc's primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Avadel Pharmaceuticals plc is headquartered in IE, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Avadel Pharmaceuticals plc is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Taking Reduction Action?

Similar Organizations

Ethypharm SAS

FR
Chemicals nec
Updated 1 day ago

OctoPlus N.V.

NL
Chemicals nec
Updated about 1 month ago
DitchCarbon Score

Teva Pharmaceuticals

IL
Chemicals nec
Updated about 3 hours ago

Nautilus Biotech S.A.

FR
Health and social work services (85)
Updated 13 days ago

Abeona Therapeutics Inc.

US
Health and social work services (85)
Updated 6 days ago

DURECT Corporation

US
Chemicals nec
Updated 6 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers